Pediatrix appoints Mark Ordan as CEO, expects 2024 adjusted EBITDA to exceed $215M guidance

Pediatrix Medical Group, Inc.

Mark S. Ordan returns as CEO effective immediately, succeeding James D. Swift who will assist transition.
2024 adjusted EBITDA expected at high end of $205M-$215M range or possibly above; results due Feb 20.
Company refocusing on hospital relationships, divesting primary/urgent care clinics, and restructuring leadership.
Ordan led Pediatrix restructuring as CEO from 2020-2022 and has turnaround experience at Sunrise, ManorCare.
Board cites need to accelerate strategy for shareholder value; Ordan served as Executive Chair since Oct 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.